INT182636

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.29
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 16
Total Number 20
Disease Relevance 17.50
Pain Relevance 0.84

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (TNFSF11) intracellular (TNFSF11) cell-cell signaling (TNFRSF11A)
response to stress (TNFSF11) cytoplasm (TNFSF11) extracellular space (TNFSF11)
Anatomy Link Frequency
osteoclast 8
macrophage 2
TNFSF11 (Homo sapiens)
TNFRSF11A (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 79 95.32 Very High Very High Very High
Osteoarthritis 107 88.60 High High
anticonvulsant 1 88.04 High High
corticosteroid 10 70.56 Quite High
Inflammation 24 70.16 Quite High
cva 55 40.44 Quite Low
chemokine 18 11.68 Low Low
headache 10 8.32 Low Low
Pain 24 6.08 Low Low
antagonist 37 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Metastasis 746 99.36 Very High Very High Very High
Osteoporosis 957 99.16 Very High Very High Very High
Disorders Of Creatine Metabolism 10 97.40 Very High Very High Very High
Hypercalcemia 174 97.04 Very High Very High Very High
Renal Failure 5 96.08 Very High Very High Very High
Apoptosis 58 95.96 Very High Very High Very High
Necrosis 26 93.52 High High
Prostate Cancer 199 93.36 High High
Cancer 546 93.16 High High
Alopecia 5 90.12 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
On the other hand, OPG is considered a decoy receptor that blocks the binding of RANKL to the RANK receptor, located on osteoclast precursors, thereby inhibiting the terminal stage of osteoclastic differentiation and suppressing its activation as well as inducing the apoptosis of mature osteoclasts.
RANKL Binding (binding) of RANK in osteoclast associated with osteoporosis and apoptosis
1) Confidence 0.29 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2246236 Disease Relevance 1.23 Pain Relevance 0.29
A prior study in our laboratory using a mouse intratibial injection model of metastasis demonstrated that blocking the RANK-RANKL interaction by RANK-Fc (a recombinant soluble fusion protein consisting of extracellular domain of RANK coupled with the Fc domain of human IgG) limits the formation of osteolytic bone lesions [44].
RANKL Binding (interaction) of RANK-Fc associated with metastasis
2) Confidence 0.19 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924520 Disease Relevance 1.33 Pain Relevance 0.04
RANK-RANKL interaction in the presence of macrophage colony-stimulating factor activates multiple intracellular signaling cascades (nuclear factor-?
RANKL Binding (interaction) of RANK in macrophage
3) Confidence 0.18 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924520 Disease Relevance 0.69 Pain Relevance 0
OPG is a negative regulator of the RANK/RANKL pathway and prevents RANK-RANKL interaction by sequestering RANKL.
RANKL Binding (interaction) of RANK
4) Confidence 0.18 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924520 Disease Relevance 0.76 Pain Relevance 0.04
RANK-RANKL interaction in the presence of macrophage colony-stimulating factor activates multiple intracellular signaling cascades (nuclear factor-?
RANKL Binding (interaction) of RANK in macrophage
5) Confidence 0.18 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924520 Disease Relevance 0.69 Pain Relevance 0
OPG is a negative regulator of the RANK/RANKL pathway and prevents RANK-RANKL interaction by sequestering RANKL.
RANKL Binding (interaction) of RANK
6) Confidence 0.18 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924520 Disease Relevance 0.76 Pain Relevance 0.04
A prior study in our laboratory using a mouse intratibial injection model of metastasis demonstrated that blocking the RANK-RANKL interaction by RANK-Fc (a recombinant soluble fusion protein consisting of extracellular domain of RANK coupled with the Fc domain of human IgG) limits the formation of osteolytic bone lesions [44].
RANKL Binding (interaction) of RANK associated with metastasis
7) Confidence 0.18 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924520 Disease Relevance 1.32 Pain Relevance 0.04
A prior study in our laboratory using a mouse intratibial injection model of metastasis demonstrated that blocking the RANK-RANKL interaction by RANK-Fc (a recombinant soluble fusion protein consisting of extracellular domain of RANK coupled with the Fc domain of human IgG) limits the formation of osteolytic bone lesions [44].
RANKL Binding (interaction) of RANK associated with metastasis
8) Confidence 0.18 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924520 Disease Relevance 1.32 Pain Relevance 0.04
Binding of RANKL to RANK on the surfaces of osteoclast precursors will trigger maturation, activation, and prolonged survival of these cells.
RANKL Binding (Binding) of RANK in osteoclast
9) Confidence 0.18 Published 2010 Journal BMC Urol Section Body Doc Link PMC2882358 Disease Relevance 1.15 Pain Relevance 0
B (RANK) ligand (RANKL), are known to induce the differentiation of monocytes/macrophages into osteoclasts; whereas osteoprotegerin (OPG), a soluble decoy receptor for RANKL that competes with RANK for RANKL binding, is known to suppress differentiation [1, 2].
RANKL Binding (competes) of RANK in osteoclasts
10) Confidence 0.17 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2829618 Disease Relevance 0.16 Pain Relevance 0.08
B (RANK) ligand (RANKL), are known to induce the differentiation of monocytes/macrophages into osteoclasts; whereas osteoprotegerin (OPG), a soluble decoy receptor for RANKL that competes with RANK for RANKL binding, is known to suppress differentiation [1, 2].
RANKL Binding (competes) of RANK in osteoclasts
11) Confidence 0.17 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2829618 Disease Relevance 0.16 Pain Relevance 0.08
RANKL exists either as a membrane bound or a soluble isoform, and it is the principal ligand for RANK [36].
RANKL Binding (ligand) of RANK
12) Confidence 0.17 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924520 Disease Relevance 0.92 Pain Relevance 0
RANKL, in turn, binds to its receptor, RANK, on osteoclast lineage cells.
RANKL Binding (binds) of RANK in osteoclast
13) Confidence 0.06 Published 2004 Journal International Journal of Medical Sciences Section Body Doc Link PMC1074710 Disease Relevance 0.62 Pain Relevance 0
B (RANK) and its ligand (RANKL), along with another cellular moiety - osteoprotegerin (OPG) - were found to be important participants in osteoclast differentiation and proliferation.
RANKL Binding (ligand) of RANK in osteoclast
14) Confidence 0.06 Published 2009 Journal Pediatr Rheumatol Online J Section Body Doc Link PMC2768686 Disease Relevance 1.59 Pain Relevance 0.18
This antibody, named denosumab, has been shown to specifically bind to RANKL with a very high affinity, preventing its interaction with the receptor RANK.
RANKL Binding (bind) of RANK
15) Confidence 0.06 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 0.73 Pain Relevance 0
Blockade of the RANK—RANK ligand (RANKL) pathway
RANKL Binding (ligand) of RANK
16) Confidence 0.05 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 1.04 Pain Relevance 0
Blockade of the RANK—RANK ligand (RANKL) pathway
RANKL Binding (ligand) of RANK
17) Confidence 0.05 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 0.99 Pain Relevance 0
OPG competitively inhibits the binding of RANKL to RANK on osteoclasts and their precursors.
RANKL Binding (binding) of RANK in osteoclasts
18) Confidence 0.05 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 0.84 Pain Relevance 0
This antibody, named denosumab, has been shown to specifically bind to RANKL with a very high affinity, preventing its interaction with the receptor RANK.
RANKL Binding (interaction) of RANK
19) Confidence 0.04 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 0.72 Pain Relevance 0
RANKL stimulates osteoclastogenesis and osteoclast function by binding to the cell surface RANK located on osteoclast precursors and osteoclasts – the interaction necessary for the formation of osteoclasts, osteoclast survival, and bone resorption [35-37].
RANKL Binding (binding) of RANK in osteoclast associated with hypercalcemia
20) Confidence 0.03 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2483463 Disease Relevance 0.41 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox